PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE) Article

International Collaboration

cited authors

  • Stewart, Michael W.; Rosenfeld, Philip J.; Penha, Fernando M.; Wang, Fenghua; Yehoshua, Zohar; Bueno-Lopez, Elena; Lopez, Pedro F.

fiu authors

publication date

  • 2012

Digital Object Identifier (DOI)

start page

  • 434

end page

  • 457

volume

  • 32

issue

  • 3

research area